Helmholtz Munich, together with the University of Münster and ITM Isotope Technologies Munich SE (ITM), has reported updated preliminary results from a Phase 1 clinical trial evaluating ITM-31, a targeted radiotherapy for glioblastoma. The treatment…
Read more